{"entity":{"id":"lisata","kind":"company","name":"Lisata Therapeutics","aka":["Lisata Therapeutics, Inc.","Caladrius Biosciences","Cend Therapeutics"],"tldr":"Lisata is a New Jersey biotech developing certepetide, a peptide that opens up the dense stroma of pancreatic tumours so chemotherapy can reach the cancer cells; it is tested with gemcitabine and nab-paclitaxel.","summary":"Lisata Therapeutics, formed when Caladrius Biosciences merged with Cend Therapeutics in 2022 and based in Basking Ridge, New Jersey, develops certepetide (LSTA1, formerly CEND-1), a cyclic peptide that binds alpha-v integrins and neuropilin-1 to increase drug penetration into solid tumours. It is tested in metastatic pancreatic cancer with standard chemotherapy and in other stroma-rich tumours, registered on ClinicalTrials.gov under Lisata as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.lisata.com"},{"label":"ClinicalTrials.gov: trials led by Lisata Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Lisata%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Basking Ridge, NJ","country":"US","companyType":"biotech","website":"https://www.lisata.com","stage":"public","investors":[],"funding":[]},"route":"/companies/lisata/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}